Korean Chinese Japanese
  • Economy
  • Politics
  • Society
  • Securities
  • Real estate
  • Culture
  • Entertainment
  • Sports
  • Opinion
Korean Chinese Japanese
Economy Corporation Pharma & Bio
Society Politics IT·Science
Securities Real Estate Global
Opinion Entertainment Sports Culture
Video Auto in Golf in
PHARM EDAILY Market in TheBeLT
Corporation
Lifestyle

Two Startups Incubated by HITEJINRO to Receive Government R&D Funding

Two startups invested in and nurtured by HITEJINRO(000080)have been selected for the government’s technology startup support program and will receive up to 2.3 billion won in research and development …
  • 2026-09-29 15:31:23
  • Kim Ji-woo
Lifestyle

PROTIA Announces 50% Stock Split... ‘Declares First Year of Shareholder Returns’

In-vitro diagnostics specialist PROTIA(303360)has decided to conduct a 50% stock split—allocating 0.5 shares for every 1 common share—marking the official launch of its shareholder-friendly management…
  • 2026-09-29 14:51:03
  • YU JIN-HEE
Lifestyle

SAMLIP Sets 2030 Revenue Target of 4.5 Trillion Won… Aims for 30% Dividend Payout Ratio

SPC SAMLIP(005610)has set a goal of achieving consolidated revenue of 4.5 trillion won and an operating profit margin of 4.4% by 2030. The company plans to enhance shareholder value by expanding its g…
  • 2026-09-29 14:07:57
  • Kim Ji-woo
Lifestyle

"Kkobuk Chips" Instead of "Masita"... Why "Hangul" Is Printed on Overseas Snack Packages

The terms “Jjipmeok” and “Daebak” are appearing on snack packaging sold overseas, and product names previously used locally are being changed to Korean names. This strategy leverages the Korean alphab…
  • 2026-09-29 10:25:07
  • Kim Ji-woo
Lifestyle

Cellbion Co., Ltd Receives Phase 3 IND Approval for Prostate Cancer Treatment… “We Will Clearly Demonstrate Its Value”

#Cellbion Co., Ltd, a company specializing in radiopharmaceuticals (RPT), has cleared the final clinical hurdle for its next-generation prostate cancer drug, setting the stage for a quantum leap in it…
  • 2026-09-29 08:21:02
  • YU JIN-HEE
Lifestyle

Vaxcell-Bio Therapeutics: Why It Filed for a ‘Clinical Trial’ Despite Risk Adjustments for VCB-1102

Vaxcell-Bio Therapeutics(323990)is launching additional clinical trials, including a controlled study, to enter the market for the treatment of advanced liver cancer with its core pipeline product, th…
  • 2026-09-29 08:16:02
  • Kim Jinsoo
Lifestyle

PROTEINA CO., LTD. Benefits from AI-Driven New Drug Development… Ingenia Highlights the Technological Value of Its Global Phase 3 Trial [Bio Spotlight]

On the 23rd, the domestic pharmaceutical and life sciences sectors showed mixed trends. The life sciences sector rose 0.64%. Of the 92 stocks in the sector, 53 rose, 8 remained unchanged, and 31 fell,…
  • 2026-09-29 07:31:02
  • KIM JI-WAN
Lifestyle

Kim Seong-yeon, Largest Shareholder of OSCOTEC Inc., Joins Forces with Second-Largest Shareholder to Restructure the Board of Directors

Kim Seong-yeon, a director at Genosco and the only son and largest shareholder of Kim Jeong-geun, the former founder of OSCOTEC Inc.(039200), is moving to restructure the board of directors to gain a …
  • 2026-09-28 21:32:02
  • Kim Jinsoo
Lifestyle

Contract Worker Killed in Pinch Accident at OTOKI Affiliate Factory

A contract worker in his 40s died while receiving treatment after being caught in a product loading machine at a factory operated by OTOKI SF, an affiliate of Ottogi(007310). OTOKI CI. (Photo court…
  • 2026-09-28 16:14:32
  • Kim Ji-woo
Lifestyle

SCL Science Partners with Thailand’s Meditop Inc. to Expand Hemostatic Agent Business into Southeast Asia

SCL Science(246960)is pursuing entry into the Thai market with its absorbable hemostatic agent, InnoSEAL Plus DL. MOU signing ceremony between companies for the “Thailand Market Development Mission…
  • 2026-09-28 13:48:02
  • KIM JI-WAN
prev 31 32 33 34 35 36 37 38 39 40 next

PHARM EDAILY

Shorts

EDAILY
  • 92, Tongil-ro, Jung-gu, Seoul, Korea
  • +82 2 3772 0114
  • webmaster@edaily.co.kr

※ This article has been translated using AI technology for the convenience of readers.

EDAILY provides this translation on an “as is” basis and makes no warranties, express or implied, regarding its accuracy, reliability, completeness, merchantability, or fitness for a particular purpose.
Due to the limitations of machine translation, the translated content may differ from the original Korean article. In the event of any discrepancy, the original Korean version shall prevail.
EDAILY shall not be liable for any loss or damage arising from the use of, or reliance on, the translated content.

© 2026 Copyrights by edaily. All Rights Reserved.
Korea China Japan
English